Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/127387
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saro, C | en_US |
dc.contributor.author | Ceballos Santos, Daniel Sebastián | en_US |
dc.contributor.author | Muñoz, F | en_US |
dc.contributor.author | De la Coba, C | en_US |
dc.contributor.author | Aguilar, MD | en_US |
dc.contributor.author | Lázaro, P | en_US |
dc.contributor.author | Iglesias Flores, E | en_US |
dc.contributor.author | Barreiro de Acosta, M | en_US |
dc.contributor.author | Hernández Durán, MD | en_US |
dc.contributor.author | Barrio, J | en_US |
dc.contributor.author | Bode Riestra, Antonio | en_US |
dc.contributor.author | Salazar, LF | en_US |
dc.date.accessioned | 2023-10-25T10:41:13Z | - |
dc.date.available | 2023-10-25T10:41:13Z | - |
dc.date.issued | 2015 | en_US |
dc.identifier.issn | 1078-0998 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/127387 | - |
dc.description.abstract | Background: This study examines the resources utilization in patients with Crohn's disease (CD) during the year before (Y - 1) and after (Y + 1) starting treatment with adalimumab and the drug's efficiency. Methods: Observational, multicenter, prospective cohort study of patients with CD naive to biological drugs. The proportion of patients with CD Activity Index (CDAI) <150 was considered as the effectiveness variable. Costs considered were direct costs (DC) related to the use of health care resources, and indirect costs (IC) related to sick leave in Y - 1 and Y + 1. Adalimumab efficiency was estimated as the incremental cost/effectiveness ratio. A deterministic sensitivity analysis was performed building 3 scenarios: base case, the least favorable, and the most favorable case for adalimumab. Results: In the cohort of 126 patients (50.8% men; age 39.1 ± 13.8 yr), the proportion of patients in remission increased from 34.1% by the end of Y - 1 to 83.3% by the end of Y + 1. Although the DC increase by the use of adalimumab, the use of doctor visits, emergency room visits, laboratory tests, diagnostic examinations, and nonbiological drug treatment were lower (P < 0.05) in Y + 1 than Y - 1. In the base case scenario, considering only DC, the incremental cost/effectiveness ratio was €31,308 and including IC, it was €28,936. In patients with CDAI > 150 at the onset, incremental cost/effectiveness ratio was €20,119 and €18,223, considering DC alone or included IC, respectively. Conclusions: In patients with CD, adalimumab increases pharmacological costs at the expense of biological therapy but reduces the cost of other drugs, the use of health care resources, and IC. Adalimumab efficiency is 30% greater in patients with CDAI > 150. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Inflammatory Bowel Diseases | en_US |
dc.source | Inflammatory Bowel Diseases, [ISNN 1078-0998], v. 21 (7), p. 1631-1640, (July 2015) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject.other | Adalimumab | en_US |
dc.subject.other | Crohn's disease | en_US |
dc.subject.other | IBD | en_US |
dc.subject.other | Resources utilization | en_US |
dc.title | Resources utilization and costs the yearbBefore and after starting treatment with Adalimumab in Crohn's Disease patients | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1097/MIB.0000000000000413 | en_US |
dc.identifier.pmid | 25961910 | - |
dc.identifier.scopus | 2-s2.0-84932120842 | - |
dc.identifier.isi | WOS:000356602200018 | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.identifier.issue | 7 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.utils.revision | Sí | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 2,348 | |
dc.description.jcr | 4,358 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0003-2384-4524 | - |
crisitem.author.fullName | Ceballos Santos, Daniel Sebastián | - |
crisitem.author.fullName | Bode Riestra,Antonio | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
7
checked on Aug 25, 2024
WEB OF SCIENCETM
Citations
6
checked on Aug 25, 2024
Page view(s)
71
checked on May 11, 2024
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.